| Heading: |
Drugs: Licensing |
| Question ID: |
1807388 |
| UIN: |
55821 |
| House: |
Commons |
| Date tabled: |
2025-05-30 |
| Asking Member ID: |
5300 |
| Asking Member display name: |
Kevin McKenna
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Kevin McKenna
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the the approval process of (a) high tariff drugs (b) the use of Obinutuzumab in patients with lupus who have experienced severe infusion reactions with rituximab. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-06-06 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The National Institute for Health and Care Excellence (NICE) is the independent body that makes recommendations on whether new licensed medicines, including high cost medicines, should be routinely funded by the National Health Service in England, based o... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |